secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2021-10-27T23:59:59+00:00
Accession:  0001099800-21-000024
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Lifesciences Q3 sales up 15% to $1.3B; EPS $0.54; guidance reaffirmed
-----------------------------------------------------------------------------

- Q3 sales $1.3B, up 15% reported (14% underlying); TAVR sales $858M, up 15% (14% underlying).
- Adjusted EPS $0.54; full-year 2021 sales guidance unchanged at $5.2-$5.4B; adjusted EPS guided to high end of $2.07-$2.27.
- TMTT sales $22M; company on track for U.S. approval of PASCAL platform for degenerative mitral regurgitation late 2022.
- Free cash flow $471M in Q3, $1.1B YTD; cash and investments $3.1B, total debt $596M.
- Q4 2021 guidance: sales $1.30-$1.38B, TAVR $850-$910M, adjusted EPS $0.53-$0.59.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980021000024/0001099800-21-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980021000024/ew-20211027.htm
  HTML page:      https://secwatch.observer/filing/0001099800-21-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer